GEG Tech and EPFL signed a collaborative research agreement

GEG Tech and EPFL signed a collaborative research agreement - Corporate News

Brisken Lab, EPFL, and GEG Tech have established a collaboration in the field of breast cancer. Breast cancer affects one women in twelve during her lifetime and is now the cancer the most widely in the world (WHO 2021). The design of new therapeutic strategies against breast cancer is a huge challenge and represents a […]

World Vaccine Congress Europe, Barcelonna

World Vaccine Congress Europe, Barcelonna - Corporate News

Happy to announce the presence of Nicolas Grandchamp at the World Vaccine Congress Europe, October 17-19, 2023, Barcelona. He will take advantage of this congress to present our latest results concerning the use of our property mRNA delivery platforms in vaccination.

ISCT 2023, Paris

ISCT 2023, Paris - Corporate News

We are pleased to announce the presence of our CSO, Nicolas Grandchamp, PhD at the ISCT congress in Paris, from May 31 to June 3.

GEG-Tech Signs Distribution Agreement with Tebu-Bio


GEG-tech’s agreement with tebu-bio expands the distribution of advanced vectorisation systems & tools, designed by GEG-tech (genetic engineering lab) into the European Market. GEG-tech, the technology leader in advanced lentiviral vectorisation systems, announces a distribution agreement with tebu-bio to bolster its coverage of the European Market. tebu-bio, is a pan-european distributor of speciality real agents […]

Innovation in cancerology: meeting in Monaco


GEG Tech will be attending the 14th Biennale Monegasque de Cancerologie. It will take place at the end on Januray 2020 in Monaco. More than 1300 participants will be gathering and discussing the evolution and progresses of cancerology. Various themes will be discussed, among them last innovations and new molecules, news in hematology, access to […]

Gene therapy: An Extensive Overview


Recent advances in the field of genetic engineering are expanding the capability of gene therapy to treat diseases, notably those previously unreachable. As a proof, the last two years saw the number of marketing authorization for gene therapy products significantly rise. Last month, Novartis has obtained Canadian approvement for its CAR-T Therapy, Kymriah. For its […]